TY - JOUR
T1 - Design and validation of a patient-reported outcome measure scale in acute pancreatitis
T2 - The PAN-PROMISE study
AU - De-Madaria, Enrique
AU - Sánchez-Marin, Claudia
AU - Carrillo, Irene
AU - Vege, Santhi Swaroop
AU - Chooklin, Serge
AU - Bilyak, Andriy
AU - Mejuto, Rafael
AU - Mauriz, Violeta
AU - Hegyi, Peter
AU - Márta, Katalin
AU - Kamal, Ayesha
AU - Lauret-Braña, Eugenia
AU - Barbu, Sorin T.
AU - Nunes, Vitor
AU - Ruiz-Rebollo, M. Lourdes
AU - Garciá-Rayado, Guillermo
AU - Lozada-Hernandez, Edgard E.
AU - Pereira, Jorge
AU - Negoi, Ionut
AU - Espina, Silvia
AU - Hollenbach, Marcus
AU - Litvin, Andrey
AU - Bolado-Concejo, Federico
AU - Vargas, Rómulo D.
AU - Pascual-Moreno, Isabel
AU - Singh, Vikesh K.
AU - Mira, José J.
N1 - Publisher Copyright:
©
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Objective This study aimed to develop and validate a patient-reported outcome measure (PROM) in acute pancreatitis (AP) as an endpoint centred on the patient. Design A PROM instrument (PAtieNt-rePoRted OutcoMe scale in acute pancreatItis, an international proSpEctive cohort study, PAN-PROMISE scale) was designed based on the opinion of patients, professionals and an expert panel. The scale was validated in an international multicentre prospective cohort study, describing the severity of AP and quality of life at 15 days after discharge as the main variables for validation. The COSMIN (COnsensus-based Standards for the selection of health status Measurement INstruments) methodology was applied. Both the design and validation stages considered the content and face validity of this new instrument; the metric properties of the different items, reliability (reproducibility and internal consistence), the construct, structural and criterion validity, responsiveness and interpretability of this scale. Results PAN-PROMISE consists of a seven-item scale based on the symptoms that cause the most discomfort and concern to patients with AP. The validation cohort involved 15 countries, 524 patients. The intensity of symptoms changed from higher values during the first 24 hours to lower values at discharge and 15 days thereafter. Items converged into a unidimensional ordinal scale with good fit indices. Internal consistency and split-half reliability at discharge were adequate. Reproducibility was confirmed using test-retest reliability and comparing the PAN-PROMISE score at discharge and 15 days after discharge. Evidence is also provided for the convergent-discriminant and empirical validity of the scale. Conclusion The PAN-PROMISE scale is a useful tool to be used as an endpoint in clinical trials, and to quantify patient well-being during the hospital admission and follow-up.
AB - Objective This study aimed to develop and validate a patient-reported outcome measure (PROM) in acute pancreatitis (AP) as an endpoint centred on the patient. Design A PROM instrument (PAtieNt-rePoRted OutcoMe scale in acute pancreatItis, an international proSpEctive cohort study, PAN-PROMISE scale) was designed based on the opinion of patients, professionals and an expert panel. The scale was validated in an international multicentre prospective cohort study, describing the severity of AP and quality of life at 15 days after discharge as the main variables for validation. The COSMIN (COnsensus-based Standards for the selection of health status Measurement INstruments) methodology was applied. Both the design and validation stages considered the content and face validity of this new instrument; the metric properties of the different items, reliability (reproducibility and internal consistence), the construct, structural and criterion validity, responsiveness and interpretability of this scale. Results PAN-PROMISE consists of a seven-item scale based on the symptoms that cause the most discomfort and concern to patients with AP. The validation cohort involved 15 countries, 524 patients. The intensity of symptoms changed from higher values during the first 24 hours to lower values at discharge and 15 days thereafter. Items converged into a unidimensional ordinal scale with good fit indices. Internal consistency and split-half reliability at discharge were adequate. Reproducibility was confirmed using test-retest reliability and comparing the PAN-PROMISE score at discharge and 15 days after discharge. Evidence is also provided for the convergent-discriminant and empirical validity of the scale. Conclusion The PAN-PROMISE scale is a useful tool to be used as an endpoint in clinical trials, and to quantify patient well-being during the hospital admission and follow-up.
KW - acute pancreatitis
UR - http://www.scopus.com/inward/record.url?scp=85083162199&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2020-320729
DO - 10.1136/gutjnl-2020-320729
M3 - Article
C2 - 32245906
AN - SCOPUS:85083162199
SN - 0017-5749
VL - 70
SP - 139
EP - 147
JO - Gut
JF - Gut
IS - 1
ER -